K 093502

## 2 510(k) Summary

Date Prepared: December 23, 2009

JAN - 7 2010

Manufactured for: Vascular Solutions, Inc.

6464 Sycamore Court Minneapolis, MN 55369

Establishment Registration #2134812

Contact Person: Jennifer Ruether

Regulatory Affairs Associate

Tel: 763-656-4370 Fax: 763-656-4253

Email: jruether@vascularsolutions.com

#### General Information:

<u>Trade Name:</u> Vari-Lase Endovenous Laser Console

<u>Common Name:</u> Laser Console

Classification Name: Laser instrument, surgical, powered

(21 CFR 878.4810; Product code GEX)

Predicate Devices: K062822, Vari-Lase Endovenous Laser Console

K051996, Diomed Delta 15 Laser Console

#### **Device Description:**

The Vari-Lase Endovenous Laser Console is a software controlled diode laser that provides an output wavelength of 810 nm and operates at a maximum output of 15 W.

#### Intended Use/Indications for Use

The Vari-Lase Endovenous Laser Console is indicated for use in the treatment of varicose veins and varicosities associated with superficial reflux of the Great Saphenous Vein and for treatment of incompetence and reflux of superficial veins in the lower extremity.

#### Substantial Equivalence

The Vari-Lase Endovenous Laser Console (15 W) substantially equivalent to the currently marketed predicate device, based on comparisons of the device classifications, technological characteristics, and the Indications for Use.



Food and Drug Administration 10903 New Hampshire Avenue Document Control Room W-066-0609 Silver Spring, MD 20993-0002

Vascular Solutions, Inc. % Ms. Jennifer Ruether Regulatory Affairs Associate 6464 Sycamore Court Minneapolis, Minnesota 55369

JAN - 7 2010

Re: K093502

Trade/Device Name: Vari-Lase Endovenous Laser Console

Regulation Number: 21 CFR 878.4810

Regulation Name: Laser surgical instrument for use in general and

plastic surgery and in dermatology

Regulatory Class: Class II

Product Code: GEX

Dated: December 16, 2009 Received: December 17, 2009

#### Dear Ms. Ruether:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21)

### Page 2 - Ms. Ms. Jennifer Ruether

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="http://www.fda.gov/cdrh/mdr/">http://www.fda.gov/cdrh/mdr/</a> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Mark N. Melkerson

Director

Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

# Indications for Use